Major Players - Visceral Pain Treatment Industry

 

Over the forecast period, it is expected that the increased prevalence of Crohn's disease and IBS will fuel regional market expansion. For instance, according to estimates reported in the Gastroenterology & Hepatology Journal (G&H) in 2016, Crohn's disease is one of the most prevalent causes of visceral pain, with an estimated 400–600 cases per 100,000 people in the North American region. The Centres for Disease Control and Prevention (CDC) estimate that in 2015, about 3 million people received an IBD diagnosis, such as ulcerative colitis or Crohn's disease.

The market for Treating Visceral Pain is anticipated to reach a value of US$ 11,673.8 million in 2020 and to grow at a CAGR of 5.2% from 2020 to 2027.

Key Companies in the Visceral Pain Treatment Industry:

1. Addex Therapeutics Ltd.:

A biopharmaceutical firm is called Addex Therapeutics Ltd. The company's main goals are the research and marketing of allosteric modulators, a new class of innovative orally absorbable small molecule medications. Switzerland and Europe are part of the company's operational region. Created in 2002. Base of operations in Switzerland.  The clinical-stage pharmaceutical company Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), which is a leader in allosteric modulation-based drug discovery and development (the Company), announced today that it has issued 32,636,476 new registered shares to Addex Pharma SA, its 100% wholly-owned subsidiary, at a nominal value of CHF 0.01.

2. AstraZeneca:

AstraZeneca was created in 1999 through the union of the Swedish company Astra with the British company Zeneca Group. The company sells branded medications in a number of important therapeutic categories, including those for gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Nearly one-third of its sales originate from the United States, which is one of the largest foreign markets. Located in England, in the United Kingdom. CinCor Pharma will be acquired by AstraZeneca to bolster its cardiorenal pipeline.

3. Astellas Pharma Inc.:

Pharmacies are sold all around the world by the drug manufacturer Astellas Pharma Inc. Japan generates the great bulk of the company's sales, followed by the Americas. A minor portion of Astellas' total sales come from royalties. Oncology, urology, and transplantation are its top three therapeutic specialties by sales composition. The company's long-term growth plan includes mergers and acquisitions. In order to expand its commercialization platforms, Astellas enters into strategic alliances and licencing agreements. Head office in Japan. Astellas Signs a Final Agreement to Purchase Iveric Bio.

4. Allergan:

Owner of a pharmaceutical firm with the primary goal of producing and marketing branded medical products including drugs, devices, biologics, and surgical and regenerative treatments. The company works in the fields of gastroenterology, gastroenterology, gastroenterology, and medical aesthetics. It also provides innovative patient care that enables its clients to take advantage of the market's increased accessibility to pharmaceuticals that treat a variety of disorders. Created in 1983. Head office in Ireland.  AbbVie will acquire Allergan in a pivotal move for both businesses.

5. Chromocell Corporation:

Innovative technology is used by a developer of treatments and flavours with the goal of enhancing consumer goods and patient life. By concentrating on analgesics and rare disorders, the company's therapeutics pipeline identifies possible novel drug candidates. Created in 2002, with a headquarters in the United States. Marizyme signs an agreement to buy or licence assets with Chromocell.

6. Takeda:

Takeda: Takeda Pharmaceutical is Japan's largest pharmaceutical firm, with a fiscal 2022 sales of JPY 4 trillion. Oncology, gastroenterology, neuroscience, rare illnesses, and plasma-derived medicines are the company's five major therapeutic areas, accounting for more than 80% of sales. Its geographic footprint is well-diversified, with 50% originating in the United States, 20% in Japan, and 20% in Europe and Canada. Established in 1925. Japan is the headquarters 

7. Abbvie:

Pharmaceutical Company AbbVie, which was spun off from Abbott in early 2013, has a significant exposure to immunology and oncology, and its top product, Humira, accounts for nearly half of its current profits. The company's recent acquisition of Allergan adds several new drugs in the fields of women's health and aesthetics.

Definition: Visceral pain, 

the pain we feel when our internal organs are inflamed, diseased, damaged or injured, is by far the most common type of pain